国际妇产科学杂志

国际妇产科学杂志 ›› 2015, Vol. 42 ›› Issue (4): 457-460.

• 综述 • 上一篇    下一篇

卵巢癌转移相关分子标记物及靶向性治疗药物的研究进展

赵婷婷，沈国栋，胡卫平   

  1. 230001 合肥，安徽医科大学附属省立医院妇产科（赵婷婷，胡卫平）；安徽省立医院老年病研究所（沈国栋）
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2015-08-15 发布日期:2015-08-15
  • 通讯作者: 胡卫平

Research Progress of Ovarian Cancer Metastasis Related Molecular Markers and Targeted Therapy

ZHAO Ting-ting，SHEN Guo-dong，HU Wei-ping   

  1. Department of Obstetrics and Gynecology，Affiliated Provincial Hospital，Anhui Medical University，Hefei 230001，China（ZHAO Ting-ting，HU Wei-ping）；Institute of Geriatrics of Anhui Provincial Hospital，Hefei 230001，China（SHEN Guo-dong）
  • Received:1900-01-01 Revised:1900-01-01 Published:2015-08-15 Online:2015-08-15
  • Contact: HU Wei-ping

PDF (PC)

5364

被引次数

12

摘要： 卵巢恶性肿瘤是女性生殖系统三大恶性肿瘤之一，其死亡率居妇科肿瘤的首位，已成为威胁女性健康的重要杀手。据美国国立癌症研究院调查显示，卵巢癌是与肿瘤相关的女性五大死因之一。上皮性卵巢癌占全部卵巢癌病例的近90%，且病情进展迅速，但由于缺乏早期临床表现和特异性症状，大多数患者就诊时已是晚期，手术治疗困难，预后较差。近年卵巢癌的发病率呈逐年上升趋势，易早期转移及浸润，是造成其死亡率高的原因。卵巢癌转移等恶性生物学行为已成为其研究热点。早期发现有效的卵巢癌转移相关分子标记物并对其进行靶向治疗是提高卵巢癌患者生存率的重要方法。除目前临床应用的糖类蛋白125（CA125）外，跨膜糖蛋白（CD44）、E-钙黏蛋白和E盒结合锌指蛋白1（ZEB1）等生物学分子有望成为诊断卵巢癌早期转移的分子标记物。

关键词: 卵巢肿瘤, 肿瘤转移, 肿瘤标记, 生物学, 治疗

Abstract: Ovarian malignant tumor is one of the three big malignant tumor in female reproductive system, the mortality rate is highest in gynecological tumors, which has become a serious threat to the female body health. According to the research of National Cancer Institute, ovarian cancer is one of the five female causes of death related to tumor. Epithelial ovarian cancer accounts for nearly 90% of all cases of ovarian cancer, and progress rapidly, but due to the lack of early clinical manifestations and specific symptoms, most are already late, when the patients see the doctors, surgery is difficult, and prognosis is poor. In recent years, there is an upward trend in the incidence of ovarian cancer, and it is easy to early metastasis and infiltration, which was the cause of the high mortality rate. Research on ovarian cancer metastasis of the malignant biological behavior has become a hot field. The early detection of effective ovarian cancer transfer related molecular markers and their targeted therapy is an important way to improve the survival rate of patients with ovarian cancer. In addition to the current clinical application of CA125，CD44，E-cadherin and ZEB1 is expected to become the molecular marker of early diagnosis of ovarian cancer metastasis.

Key words: Ovarian neoplasms, Neoplasms metastasis, Tumor markers, biological, Therapy